EME. I. Malasсhenko

E. I. Malasсhenko

*This is an algorithmically generated author record based on publicly available information.

E. I. Malasсhenko has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overlap syndrome in hepatology

    by O. A. Yarmolenko, E. G. Malaeva, I. L. Mamchenko, T. V. Aleynykova, L. A. Kobruseva, I. A. Khudyakov, M. N. Menshakova, E. I. Malasсhenko

    Autoimmune liver disease is a heterogeneous group of diseases in which the body’s immune cells and antibodies are directed against its own components of the liver tissue. The main diseases from this group are: autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis. Most often there are classical monovariants of the disease, but in some cases, manifestations of two forms from the autoimmune liver disease are observed at once. The term “overlap syndrome” is used to describe such conditions. The article presents a clinical case of a combination of PBC and AIH, one of the most common overlapping syndromes in practice. Most often there are classical monovariants of the disease, but in some cases there are manifestations of two forms of autoimmune liver diseases. Overlap syndrome is a term used to describe these conditions. This article presents a clinical case of a combination of PBC and AIH, one of the most common cross-linked syndromes in practice.


  • COVID-19: the efficacy and safety of anticoagulant, glucocorticosteroid therapy and metabolic

    by Gomel State Medical University, D.P. Salivonchyk, I.о. Stoma, E.A. Dotsenko, N.N. Kudenchuk, The Main Department of Healthcare in the Gomel Region, E.I. Salivonchyk, I.A. Khudyakov, Gomel City Clinical Hospital No. 3, M.N. Menshakova, et al.

    COVID-19: эффективность и безопасность антикоагулянтной, глюкокортикоидной и метаболической терапии